Oxagen Limited is a privately held UK biopharmaceutical company developing a pipeline of novel small molecule drugs addressing asthma and other chronic allergic and inflammatory conditions. Its lead drug candidate OC000459 is a once-daily oral CRTH2 antagonist in Phase IIb clinical trials that has demonstrated efficacy in asthma, allergic rhinitis and allergic conjunctivitis along with an excellent safety profile. The Company is based in Milton Park, south of Oxford.